Tags

Type your tag names separated by a space and hit enter

Drug-Induced Liver Injury Network Causality Assessment: Criteria and Experience in the United States.

Abstract

Hepatotoxicity due to drugs, herbal or dietary supplements remains largely a clinical diagnosis based on meticulous history taking and exclusion of other causes of liver injury. In 2004, the U.S. Drug-Induced Liver Injury Network (DILIN) was created under the auspices of the U.S. National Institute of Diabetes and Digestive and Kidney Diseases with the aims of establishing a large registry of cases for clinical, epidemiological and mechanistic study. From inception, the DILIN has used an expert opinion process that incorporates consensus amongst three different DILIN hepatologists assigned to each case. It is the most well-established, well-described and vigorous expert opinion process for DILI to date, and yet it is an imperfect standard. This review will discuss the DILIN expert opinion process, its strengths and weaknesses, psychometric performance and future.

Links

  • PMC Free PDF
  • PMC Free Full Text
  • FREE Publisher Full Text
  • Authors+Show Affiliations

    University of North Carolina Liver Center, 8011 Burnett-Womack Building, Chapel Hill, NC 27599-8754, USA. paul_hayashi@med.unc.edu.

    Source

    MeSH

    Chemical and Drug Induced Liver Injury
    Consensus
    Drug-Related Side Effects and Adverse Reactions
    Expert Testimony
    Humans
    Psychometrics
    United States

    Pub Type(s)

    Journal Article
    Review

    Language

    eng

    PubMed ID

    26861284

    Citation

    Hayashi, Paul H.. "Drug-Induced Liver Injury Network Causality Assessment: Criteria and Experience in the United States." International Journal of Molecular Sciences, vol. 17, no. 2, 2016, p. 201.
    Hayashi PH. Drug-Induced Liver Injury Network Causality Assessment: Criteria and Experience in the United States. Int J Mol Sci. 2016;17(2):201.
    Hayashi, P. H. (2016). Drug-Induced Liver Injury Network Causality Assessment: Criteria and Experience in the United States. International Journal of Molecular Sciences, 17(2), p. 201. doi:10.3390/ijms17020201.
    Hayashi PH. Drug-Induced Liver Injury Network Causality Assessment: Criteria and Experience in the United States. Int J Mol Sci. 2016 Feb 4;17(2):201. PubMed PMID: 26861284.
    * Article titles in AMA citation format should be in sentence-case
    TY - JOUR T1 - Drug-Induced Liver Injury Network Causality Assessment: Criteria and Experience in the United States. A1 - Hayashi,Paul H, Y1 - 2016/02/04/ PY - 2016/01/10/received PY - 2016/01/27/revised PY - 2016/01/28/accepted PY - 2016/2/11/entrez PY - 2016/2/11/pubmed PY - 2016/11/5/medline KW - causality KW - diagnosis KW - expert opinion KW - hepatotoxicity SP - 201 EP - 201 JF - International journal of molecular sciences JO - Int J Mol Sci VL - 17 IS - 2 N2 - Hepatotoxicity due to drugs, herbal or dietary supplements remains largely a clinical diagnosis based on meticulous history taking and exclusion of other causes of liver injury. In 2004, the U.S. Drug-Induced Liver Injury Network (DILIN) was created under the auspices of the U.S. National Institute of Diabetes and Digestive and Kidney Diseases with the aims of establishing a large registry of cases for clinical, epidemiological and mechanistic study. From inception, the DILIN has used an expert opinion process that incorporates consensus amongst three different DILIN hepatologists assigned to each case. It is the most well-established, well-described and vigorous expert opinion process for DILI to date, and yet it is an imperfect standard. This review will discuss the DILIN expert opinion process, its strengths and weaknesses, psychometric performance and future. SN - 1422-0067 UR - https://www.unboundmedicine.com/medline/citation/26861284/Drug_Induced_Liver_Injury_Network_Causality_Assessment:_Criteria_and_Experience_in_the_United_States_ L2 - http://www.mdpi.com/resolver?pii=ijms17020201 DB - PRIME DP - Unbound Medicine ER -